Top Tweets for #Repeatable
You wanna train your eye to
See the move
Before the move.
SEE
EDGE
TRADE
and make a profit
#Consistently
#Repeatable
#DCVax is a #paradigmshift in #cancer from $NWBO for all #solid tumor. It is #autologous meaning ...
#moral - no questionably sourced cells
#safe - no deadly side-effects
#effective - customized just for you
#REPEATABLE - do it again overcoming resistance from mutations
🔥#DCVax is a #paradigmshift in #cancer from $NWBO for all #solid tumor. It is #autologous meaning ...
#moral - no questionably sourced cells
#safe - no deadly side-effects
#effective - customized just for you
#REPEATABLE - do it again overcoming resistance from mutations
#DCVax is a #paradigmshift in #cancer from $NWBO for all #solid tumor. It is #autologous meaning ...
#moral - no questionably sourced cells
#safe - no deadly side-effects
#effective - customized just for you
#REPEATABLE - do it again overcoming resistance from mutations
https://t.co/bkWkqMU3WX
#DCVax is a #paradigmshift in #cancer from $NWBO for all #solid tumor. It is #autologous meaning ...
#moral - no questionably sourced cells
#safe - no deadly side-effects
#effective - customized just for you
#REPEATABLE - do it again overcoming resistance from mutations
🧠 $NWBO #DCVax + Pulsed AP-1 Clamp in #Glioblastoma
Durable immune instruction, plus timed enhancer-level “recurrence arrest,” then cure-hardening with IL-7 and MRD cleanup
TL;DR 📌
Glioblastoma relapse is not mainly “antigen escape.” It is a therapy-resistant progenitor compartment that survives, then reboots the tumor by switching transcriptional state, often toward a mesenchymal, invasive, inflammatory program. Convergent evidence places AP-1 (JUN/FOS, c-JUN-centered) at the control hub of that recurrence state, including stress-induced enhancer programs.
This strategy is a sequenced control architecture:
DCVax = breadth-first immune instruction + durable surveillance. Autologous dendritic cells loaded with whole tumor lysate present a wide peptide library on MHC I and II, engaging CD8 killing plus CD4 help over repeat dosing. Clinically, DCVax-L is associated with improved survival benchmarks including 19.3 vs 16.5 months in newly diagnosed GBM and 13.2 vs 7.8 months in recurrent GBM, with a 60-month survival tail of 13.0% vs 5.7% in newly diagnosed disease.
AP-1 clamp = short, timed pulses that block “adaptive reboot.” This is state control, not cytotoxicity: the goal is to transiently suppress AP-1-dependent enhancer output during immune selection windows so the recurrence compartment cannot reprogram under pressure. The SOX21 brake demonstrates the mechanism at enhancer level, with quantitative signatures of enhancer decommissioning (reduced chromatin accessibility and reduced active enhancer marks H3K27ac and H3K4me1) and collapse of stemness, invasion, inflammatory signaling, and resistance programs.
IL-7 = cure-hardening substrate. IL-7 (CYT107) is positioned to preserve repertoire breadth and memory durability so a successful immune wave becomes sustained immune control instead of post-peak contraction into late failure.
MRD cleanup = conditional last-mile eradication. If minimal residual disease persists, escalation lanes include DC-assisted adoptive T-cell therapy for effector mass and antigen-faint killing logic (DNAM-1 and NKG2D) to extend clearance when MHC I is downregulated, plus optional pMHC or TCR-mimic deletion tools guided by what is truly presented.
Measure, pulse, repeat only when needed. Clamp pulses are tuned by AP-1 and mesenchymal program readouts and enhancer-state signatures, then re-applied only when recurrence programs re-emerge.
Bottom line: DCVax supplies the distributed, antigen-specific elimination and long-term surveillance. The AP-1 clamp prevents the recurrence compartment from adapting under that immune pressure. IL-7 locks durability. MRD lanes finish the job when biology demands it.
#DCVax is a #paradigmshift in #cancer from $NWBO for all #solid tumor. It is #autologous meaning ...
#moral - no questionably sourced cells
#safe - no deadly side-effects
#effective - customized just for you
#REPEATABLE - do it again overcoming resistance from mutations
🧬 The Trojan Vault: How $NWBO #DCVax #HealthBank Turns Tumor Banking Into Immune Infrastructure
📌 TLDR
🧊 HealthBank is not storage. It is custody.
Tumor tissue preserved in viable format under regulated chain of identity becomes therapeutic-grade starting material.
🧬 DCVax has Phase III survival data in glioblastoma.
Commercial manufacturing is licensed in the UK and expanding. Automation is advancing.
🏭 Vault + Licensed Factory = Deployment Engine.
Stored tumors can move directly into GMP manufacturing without rebuilding identity or supply chain.
🔁 Subscription economics mirror cord blood banking.
Modest upfront cost. Recurring annual storage. Low utilization, high retention, durable revenue.
🛡️ Custody creates the moat.
In autologous therapy, chain of identity and chain of custody are non-negotiable. Whoever holds the tissue holds the option.
🌍 Scalable architecture is already forming.
UK licensed facility. Automation platform. US manufacturing build-out. Trademark secured.
Bottom line:
HealthBank reframes tumor tissue from surgical waste into programmable feedstock. If tumor banking normalizes the way cord blood did, $NWBO shifts from a single-product biotech to a long-duration immune infrastructure platform.
#DCVax is a #paradigmshift in #cancer from $NWBO for all #solid tumor. It is #autologous meaning ...
#moral - no questionably sourced cells
#safe - no deadly side-effects
#effective - customized just for you
#REPEATABLE - do it again overcoming resistance from mutations
#DCVax is a #paradigmshift in #cancer from $NWBO for all #solid tumor. It is #autologous meaning ...
#moral - no questionably sourced cells
#safe - no deadly side-effects
#effective - customized just for you
#REPEATABLE - do it again overcoming resistance from mutations
$NWBO
@kshaughnessy2
@ATLnsider
@metacollectiveG
@AllaireMar73316
@biggercapital
This is how I see the coming weeks and months unfolding.
I’m not trying to predict the exact timing of the news (been wrong 100% of the time).
I’m focused on identifying the typical pattern that precedes a binary event in biotech.
What I know is Biotech history repeats the same pattern over and over:
Phase #1 Compression
Volatility contracts, stock down +20% over a short period before a binary news.
Price drifts.
Conviction weakens.
Phase #2 Catalyst
Then the event hits and uncertainty disappears.
Phase #3 Expansion
The remaining variable is the magnitude of the repricing.
From theory to reality
$NWBO is currently trading in that compression phase (phase #1):
Low liquidity.
Pre-regulatory backdrop.
That doesn’t confirm outcome.
In binary biotech, price often reflects risk adjustment and not final probability.
When the binary resolves, repricing is violent:
Watch the volume.
Watch the behavior around the catalyst.
And most important, if you’re bullish on the outcome, ignore the noise.
#DCVax It is a paradigm shift in cancer from $NWBO.
#moral: it is autologous - no questionably sourced cells
#safe: it is autologous - no deadly side-effects
#effective: it is autologous - customized just for you
#REPEATABLE: can be done again overcoming cancer as it mutates
#DCVax It is a paradigm shift in cancer from $NWBO.
#moral: it is autologous - no questionably sourced cells
#safe: it is autologous - no deadly side-effects
#effective: it is autologous - customized just for you
#REPEATABLE: can be done again overcoming cancer as it mutates
#dcvax $nwbo #gbm
Excellent post by @TommyBaxendale :
I come bearing good news. So after the publishing of the National Cancer Plan it was clear to me that almost the entire plan's applicability to NWBO and DCVax rested on whether or not DCVax would be eligible to join the NHS's Cancer Vaccine Launch Pad (CVLP).
If you remember, back in May last year I emailed the CVLP to ask “whether the scope of the CVLP will be expanded in due course to include dendritic cell vaccines instead of its present focus on just mRNA based vaccines?”, this was their answer in August:
“Thank you for your email regarding the NHS Cancer Vaccines Launch Pad (CVLP). The NHS Cancer Vaccine Launchpad (CVLP) is a platform facilitating access to clinical trials of cancer vaccine treatment where the cancer vaccines are created by analysing a patient’s tumour and identifying specific mutations that are unique to that cancer, then using that information to create a vaccine tailored to the patient.
The NHS CVLP was designed with lessons learnt by the NHS in delivering coronavirus vaccine studies. The platform is being built to be agnostic to the commercial company and clinical trials while ensuring it is patient-focussed with equity of access.
The scope of the Cancer Vaccine Launch Pad (CVLP) has now been expanded to include cancer immunotherapies and cancer vaccines or other personalised immunotherapy that require molecular profiling or genetic sequencing.”
Although promising on the face of it, I found this answer a little difficult to interpret due to the Oxford comma conundrum. Did they mean that the CVLP had been expanded to include cancer immunotherapies and cancer vaccines or other personalised immunotherapy all of which that specifically and only require molecular profiling or genetic sequencing as part of the treatment process, or, did they mean that the CVLP had been expanded to include:
i) cancer immunotherapies
ii) cancer vaccines
iii) other personalised immunotherapy that require molecular profiling or genetic sequencing
It’s a subtle contrast, but it makes ALL the difference as to whether DCVax would fall under the CVLP umbrella or not.
Having read the National Cancer Plan and seeing how much of the Plan hinged around the CVLP it actually made me quite uncomfortable to consider that if read the first way - written without any commas - there was the potential for the National Cancer Plan to in fact be completely snubbing Dendritic Cell Therapies/ NWBO and concentrating entirely on mRHA and CAR-T. So, I wrote back to the CVLP and asked them:
"Dear CVLP Team,
Thank you for your previous reply regarding the scope of the CVLP.
I am writing to seek specific technical clarification on the definition you provided: "cancer immunotherapies and cancer vaccines or other personalised immunotherapy that require molecular profiling or genetic sequencing."
There is some ambiguity in whether the requirement for "molecular profiling/genetic sequencing" applies to all categories in that list, or solely to the "other" category.
Specifically, I am asking if the CVLP infrastructure allows for the inclusion of autologous whole-tumour lysate dendritic cell vaccines.
As you are aware, this class of treatment (unlike mRNA or peptide vaccines) is biomarker-agnostic and polyclonal. It relies on the patient’s physical tumour tissue (lysate) rather than a digital genomic sequence to manufacture. Therefore, it does not require the specific genomic profiling workflow currently used for BioNTech/Moderna trials.
Could you please confirm strictly:
1. Is the CVLP technically capable of onboarding a trial for a therapy that does not utilize a genomic sequence for manufacturing (i.e., a tissue-based lysate vaccine)?
2. Does the "expanded scope" you mentioned explicitly exclude treatments that are effectively "ready" (Phase 3 data available) but awaiting regulatory/funding clearance, such as DCVax-L?
Given the government’s recent announcement regarding "Greater access to breakthrough trials," it is vital for patients to understand if the CVLP is exclusively a genomic-match engine, or if it is truly open to all forms of personalised immunotherapy.
I look forward to your specific guidance on this technical distinction."
And this morning I already received a reply from them, thankfully about 3 months quicker than the last time I emailed (see attached).
So with this in mind it is clear that the UK National Cancer Plan is also very much geared towards DCVax. I believe this means the following:
1. Immediate Access to the National Cancer Plan via the CVLP. The CVLP is the central mechanism in the National Cancer Plan for fast-tracking cancer vaccines, which means DCVax-L (or future iterations like DCVax-Direct) can utilise the CVLP infrastructure. This infrastructure includes patient identification (finding eligible patients via NHS data) and referral networks (sending them to trial sites). The plan effectively offers NWBO a government-funded recruitment engine.
2. Molecular Profiling is an eligibility tool, not a barrier. The email clarifies that molecular profiling is used for eligibility or stratification, not just manufacturing. Even though DCVax-L is biomarker agnostic (works for everyone), the CVLP can still use profiling to monitor patients. For example, they can use the CVLP's genomic testing to track how well DCVax-L works in patients with specific mutations (like IDH-wildtype vs mutant). This turns the genomic focus of the plan from a barrier into a validation tool for NWBO.
3. Funding for infrastructure should benefit Advent Bioservices. The Plan commits to investing in "aseptic medicines production hubs" (Action 8) and reducing setup times for trials. Since DCVax-L is now confirmed to be in the CVLP remit, the government’s push to build infrastructure for "personalised immunotherapies" directly supports the logistics NWBO needs. The hiring at Advent Bioservices (Grade C suites, admin coordinators) aligns perfectly with a facility preparing to plug into this national network.
4. The Rare Cancers Fast-Track (Action 13). The confirmation that DCVax is entirely eligible for the CVLP strengthens the link to the Rare Cancers Bill, which is being read in Parliament in 2 days. The Plan explicitly says it will "implement the Rare Cancers Bill" and "review market authorisations." Now that we know the NHS will include lysate vaccines in their Launch Pad, the MAA is far more likely to be favourable, particularly when keeping in mind the existing DCVax NHS IFR list inclusion.
5. Commercial & Trial Implications. The email invited me to "discuss the potential for the CVLP to support a specific clinical trial." This looks like an open door for NWBO to run a Phase 4 (Post-Approval) trial or a combo therapy trial through the CVLP. If the MHRA was to grant NWBO a Conditional Approval (requiring more data), NWBO can now seemingly use the CVLP to gather that data. This removes the massive cost and logistical burden of running a post-market registry independently.
The National Cancer Plan is no longer seemingly just a brochure for mRNA. It is a funded infrastructure project that has just explicitly just confirmed that it will include autologous whole-tumour lysate dendritic cell vaccines.
The National Cancer Plan doesn't name dendritic cell vaccines or DCVax because it's a policy document and DCVax is so far yet to be approved, but the category “immunotherapies with molecular profiling elements" has now been officially widened to include it.
It seems that the combination of the imminent MHRA decision + confirmed potential for DCVax's CVLP inclusion + Advent’s readiness creates a complete commercial ecosystem for DCVax-L in the UK supported by the UK's new National Cancer Plan. We are now looking at a potential scenario where the UK government could effectively become NWBO's funding partner to help roll out DCVax to UK patients and help fund further trials, and I don't believe I am exaggerating by saying this.
GLTA
https://t.co/c5iwS64OTD
#DCVax It is a paradigm shift in cancer from $NWBO.
#moral: it is autologous - no questionably sourced cells
#safe: it is autologous - no deadly side-effects
#effective: it is autologous - customized just for you
#REPEATABLE: can be done again overcoming cancer as it mutates
MHRA just posted an updated register of licensed manufacturing sites for Feb. Advent is listed. Obviously approval is the main focus, but this isn’t something to be ignored. Bullish.😄
https://t.co/OdaaB1vDWi
#DCVax It is a paradigm shift in cancer from $NWBO.
#moral: it is autologous - no questionably sourced cells
#safe: it is autologous - no deadly side-effects
#effective: it is autologous - customized just for you
#REPEATABLE: can be done again overcoming cancer as it mutates
#DCVax It is a paradigm shift in cancer from $NWBO.
#moral: it is autologous - no questionably sourced cells
#safe: it is autologous - no deadly side-effects
#effective: it is autologous - customized just for you
#REPEATABLE: can be done again overcoming cancer as it mutates
🧬 Cancer isn’t one disease, and patients aren’t interchangeable.
DCVax works because it treats uniqueness as the strategy, not the noise.
When the immune system is taught using your own tumor, durability stops being a coincidence and starts being the point.
@YYDSxjm #DCVax It is a paradigm shift in cancer from $NWBO.
#moral: it is autologous - no questionably sourced cells
#safe: it is autologous - no deadly side-effects
#effective: it is autologous - customized just for you
#REPEATABLE: can be done again overcoming cancer as it mutates
#DCVax It is a paradigm shift in cancer from $NWBO.
#moral: it is autologous - no questionably sourced cells
#safe: it is autologous - no deadly side-effects
#effective: it is autologous - customized just for you
#REPEATABLE: can be done again overcoming cancer as it mutates
🧬 Why Today’s #MHRA Signal Maps Directly to $NWBO #AdventBioServices + #EDEN + #DCVax
Today’s MHRA activity quietly connects the full chain that DCVax has always depended on but regulators are only now describing in public language.
The “Mila to Millions” release is not a cancer announcement. It is more consequential than that. It formalizes a regulatory shift away from approving static products and toward approving standardized, auditable manufacturing processes for individualized medicines. The MHRA is explicitly acknowledging that science is no longer the limiting factor. Systems are.
That framing is the regulatory prerequisite for autologous #ATMP platforms to scale.
DCVax does not exist as a separable drug substance. It exists as a controlled transformation of patient specific tumor material into a functional immune product. In that world, the process is the product. Without a repeatable, regulator trusted process, there is no path to scale, no path to comparability, and no path to expansion beyond the first indication.
This is where Advent and EDEN stop being supporting characters and become central infrastructure.
Advent provides the end to end regulatory spine the MHRA is implicitly asking for: GMP licensure, quality systems, chain of identity, deviation control, release discipline, and a structure that regulators can audit repeatedly without discovering drift. This is not contract manufacturing. It is regulatory continuity.
EDEN is the control layer that makes that continuity real. Its value is not automation for convenience. Its value is variance destruction. Reduced handling stress, standardized workflows, instrumented steps, and reproducibility across operators, time, and ultimately sites. EDEN turns an artisanal cellular workflow into something a regulator can approve once and trust many times.
That trust is what enables the leap MHRA is now describing: master protocols, process approval, and platform logic that can cross patients and eventually indications without restarting the regulatory clock each time.
The contrast is visible today as well.
Alongside this forward looking regulatory vision, MHRA issued a Class 2 recall for a legacy chemotherapy agent. That recall is not a scandal. It is a reminder of the fragility of batch based oncology. Centralized production, substitution risk, silent variability, and downstream clinical consequences.
Autologous immunotherapy flips that model. You cannot substitute the batch. You must control the process.
Put simply, MHRA is now describing the regulatory architecture that makes individualized immune platforms viable at scale. Advent is the facility that satisfies it. EDEN is the control system that stabilizes it. DCVax is the therapeutic platform that depends on both.
#IndividualizedMedicine #CellTherapy #ProcessApproval #Oncology #RareCancer
Mila to Millions: A New Era of Individualized Medicines https://t.co/EtYODNb8CD
#DCVax It is a paradigm shift in cancer from $NWBO.
#moral: it is autologous - no questionably sourced cells
#safe: it is autologous - no deadly side-effects
#effective: it is autologous - customized just for you
#REPEATABLE: can be done again overcoming cancer as it mutates
#DCVax It is a paradigm shift in cancer from $NWBO.
#moral: it is autologous - no questionably sourced cells
#safe: it is autologous - no deadly side-effects
#effective: it is autologous - customized just for you
#REPEATABLE: can be done again overcoming cancer as it mutates
@Siobhain_Mc @wesstreeting @NIHRresearch @CR_UK And to think the @MHRAgovuk has been in possession of an MAA from $NWBO for $DCVax-L to treat one of the deadliest forms of cancer, GBM, for over 2 years and still hasn't approved it. $DCVax is a safe and effective treatment yet languishes in a government morass. Shameful.
#DCVax It is a paradigm shift in cancer from $NWBO.
#moral: it is autologous - no questionably sourced cells
#safe: it is autologous - no deadly side-effects
#effective: it is autologous - customized just for you
#REPEATABLE: can be done again overcoming cancer as it mutates
$NWBO posted about today on Towards Healthcare's Linkedin. Specifically, what strategies the company have implemented to overcome the challenges faced with bringing a personalised immunotherapy to market.
Good to see this from a Healthcare Consulting Co
https://t.co/PpevnOOZWw
#DCVax It is a paradigm shift in cancer from $NWBO.
#moral: it is autologous - no questionably sourced cells
#safe: it is autologous - no deadly side-effects
#effective: it is autologous - customized just for you
#REPEATABLE: can be done again overcoming cancer as it mutates
$NWBO #DCVax #Murcidencel
The biggest insight is that the cancer-vaccine field is declaring a phase-change. Not “does it work in principle,” but “how do we standardize and scale it.” The agenda is coordination: research-to-clinic velocity, antigen-selection tools, delivery-platforms, and the hard-rails of funding, regulation, policy, and access.
Inside that category-level inflection, $NWBO is used as the illustrative-anchor: a 22-year GBM-survivor case tied to #DCVax-L, followed by a full platform-overview that explicitly references its UK commercial-approval application.
@kshaughnessy2 #DCVax It is a paradigm shift in cancer from $NWBO.
#moral: it is autologous - no questionably sourced cells
#safe: it is autologous - no deadly side-effects
#effective: it is autologous - customized just for you
#REPEATABLE: can be done again overcoming cancer as it mutates
Last Seen Hashtags on Sotwe
soyunuyor
Seen from Turkey
esperanzagomez
Seen from Colombia
NOlimit filter:videos
Seen from France
sonmo() +filter:native_video
Seen from Japan
留学生
Seen from Netherlands
mature feet
Seen from Turkey
GiuliaSalemi
Seen from Italy
umlugarsecreto
Seen from Brazil
YuzuProofs
Seen from Norway
mojarra
Seen from United States
Most Popular Users
Elon Musk 
@elonmusk
240.2M followers
Barack Obama
@barackobama
119.3M followers
Donald J. Trump
@realdonaldtrump
111.6M followers
Cristiano Ronaldo
@cristiano
109M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.3M followers
NASA
@nasa
92.1M followers
Justin Bieber
@justinbieber
90.6M followers
KATY PERRY
@katyperry
86.8M followers
Taylor Swift
@taylorswift13
80.6M followers
Lady Gaga
@ladygaga
72.2M followers
Kim Kardashian
@kimkardashian
69.4M followers
YouTube
@youtube
68.6M followers
Virat Kohli
@imvkohli
68.6M followers
Bill Gates
@billgates
63.4M followers
The Ellen Show
@theellenshow
62.5M followers
CNN
@cnn
61.9M followers
Neymar Jr
@neymarjr
61.1M followers
X
@x
60.9M followers
Selena Gomez
@selenagomez
59.9M followers